Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Merck (MRK) drops as full-year forecast misses consensus
February 2, 2023 6:51 AM EST(Updated - February 2, 2023 1:20 PM EST)
Shares of Merck (NYSE: MRK) tumbled more than 4% Thursday despite the New Jersey-based pharmaceutical giant reporting stronger-than-expected FQ4 results.
Merck reported Q4 EPS of $1.62 on revenue of $13.8 billion, beating the consensus for earnings of $1.53 on revenue of $13.65B. Molnupiravir sales fell 13% year-over-year to $825 million, still much higher than the consensus of $376M. Keytruda sales rose 19% to $5.45B, in line with the analyst... More
Merck (MRK) Tops Q4 EPS by 9c; Guides FY23 EPS Below the Street
February 2, 2023 6:31 AM ESTMerck (NYSE: MRK) reported Q4 EPS of $1.62, $0.09 better than the analyst estimate of $1.53. Revenue for the quarter came in at $13.8 billion versus the consensus estimate of $13.65 billion.
GUIDANCE:
Merck sees FY2023 EPS of $6.80-$6.95, versus the consensus of $7.36. Merck sees... More
